Susquehanna International Group, LLP Protalix Bio Therapeutics, Inc. Transaction History
Susquehanna International Group, LLP
- $688 Billion
- Q2 2025
A detailed history of Susquehanna International Group, LLP transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 298,567 shares of PLX stock, worth $489,649. This represents 0.0% of its overall portfolio holdings.
Number of Shares
298,567
Previous 858,650
65.23%
Holding current value
$489,649
Previous $2.2 Million
79.94%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding PLX
# of Institutions
68Shares Held
8.72MCall Options Held
168KPut Options Held
31.4K-
Jim Simons Renaissance Technologies LLC | New York, Ny1.62MShares$2.65 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL1.08MShares$1.77 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA826KShares$1.36 Million0.0% of portfolio
-
Connor, Clark & Lunn Investment Management Ltd.496KShares$813,7940.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA485KShares$795,0680.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $81.6M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...